Dana-Farber’s Breast Oncology Center· @DFCI_BreastOnc · X·· 17 hours agoScore45
Body · original
Dr. Nancy Lin (@nlinmd) at the #ESMO26 poster sessions sharing info on the new #BREnna study opening soon @DanaFarber! This phase II/III randomized study focuses on of ZN-A-1041 or tucatinib, in combination with trastuzumab + capecitabine, in patients with HER2+ locally advanced or #MetastaticBreastCancer (HER2+ LA/mBC) with or without central nervous system (#CNS) metastases.
115 views · 2 likes · 2 reposts · 0 replies
Conference abstracts
1766ROmatched by Rapid oral 1: Breast cancer, advanced stage
Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSource: Dana-Farber’s Breast Oncology Center · x.com